Delfi Diagnostics reported interim clinical-utility results for its FirstLook Lung cfDNA liquid-biopsy assay presented at the American Thoracic Society International Conference. In the cluster-randomized FIRSTLUNG trial across 28 clinics in Colorado, Florida and North Carolina, use of the blood test increased overall lung cancer screening by nearly threefold. Among nearly 3,000 patients who were behind on screening, FirstLook Lung showed about 80% sensitivity, 56% specificity and a negative predictive value of 99.8%. The company also reported a 1.5-fold rise in low-dose CT screening, with many cancers detected at stage I. Delfi said the test’s access through outpatient workflows can address under-screening and that it has submitted results to a peer-reviewed journal. The company also estimated that a 3% increase in annual screening uptake over five years could prevent slightly more than 3,000 deaths in a simulated population of 15 million.